CA Patent

CA2905181C — Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy

Assigned to MedImmune Ltd · Expires 2020-06-02 · 6y expired

What this patent protects

Disclosed herein are selected conjugates of formula (A): (See Formula A) The conjugates comprise a pyrrolobenzodiazepine (PBD) compound with a linker for connecting to a cell binding agent, wherein the linker is attached in a cleavable manner to the C7 posiiton of the PBD. The ce…

USPTO Abstract

Disclosed herein are selected conjugates of formula (A): (See Formula A) The conjugates comprise a pyrrolobenzodiazepine (PBD) compound with a linker for connecting to a cell binding agent, wherein the linker is attached in a cleavable manner to the C7 posiiton of the PBD. The cell binding agent is preferably an antibody. Also disclosed is the PBD compound with the linking unit attached and intermediates for their synthesis. The conjugates may be useful for treating a proliferative disease in a subject, preferably cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2905181C
Jurisdiction
CA
Classification
—
Expires
2020-06-02
Drug substance claim
No
Drug product claim
No
Assignee
MedImmune Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.